E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedReviewed
Standard · 3 min
Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome.
Chao, C C, Janoff, E N, Hu, S X et al. · Cytokine · 1991 · DOI
Quick Summary
This study found that immune cells from people with ME/CFS respond differently to stimulation than cells from healthy people. Specifically, when researchers activated these immune cells in the lab, they released higher levels of inflammatory molecules (IL-1 beta, IL-6, and TNF-alpha), suggesting that ME/CFS patients' immune cells may be in a heightened state of readiness. The study also found unusual patterns in a molecule called TGF-beta, which normally helps regulate immune responses.
Why It Matters
This study provides early mechanistic evidence that ME/CFS involves measurable immune dysregulation—specifically a primed innate immune response—rather than purely psychological causes. Understanding how immune cells behave abnormally in ME/CFS may eventually lead to biomarkers for diagnosis and targeted therapeutic interventions.
Observed Findings
Serum TGF-beta was significantly higher in CFS patients than controls (290 ± 46 pg/mL vs 104 ± 18 pg/mL).
Lipopolysaccharide-stimulated release of IL-1β, IL-6, and TNF-α was increased in PBMC cultures from CFS patients.
Phytohemagglutinin-stimulated IL-6 release was enhanced in CFS-derived PBMCs.
TGF-β release in response to lipopolysaccharide was depressed in PBMC cultures from CFS patients.
No differences were observed in IL-2, IL-4, or immunoglobulin production between groups.
Inferred Conclusions
Immune cells from CFS patients are primed for an exaggerated inflammatory response to immune stimuli.
There is abnormal regulation of TGF-β production both in serum (elevated) and in stimulated PBMC cultures (depressed), suggesting dysregulation of this immunomodulatory molecule.
Immunelogical abnormalities, particularly altered cytokine release patterns, may be relevant to CFS pathogenesis.
Remaining Questions
Do these cytokine abnormalities persist longitudinally, or do they fluctuate with disease activity and symptom severity?
What is the functional consequence of elevated serum TGF-β combined with depressed PBMC TGF-β release upon stimulation?
What This Study Does Not Prove
This study does not prove that immune cell dysregulation causes ME/CFS symptoms or that correcting these cytokine abnormalities will improve patient outcomes. The in vitro findings may not fully reflect what occurs in the body, and the cross-sectional design cannot establish temporal relationships or whether these immune changes persist over time.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.